Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acrylic Acid Ethyl Ester. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylic Acid Ethyl Ester SCHEMBL147655 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRHPGDTHRBALOX15 | |
| Acrylic Acid Ethyl Ester SCHEMBL146753 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRHPGDTHRBALOX15 | |
| Acrylic Acid Ethyl Ester SCHEMBL443509 | 0.99 | ALDH1A1 (0.39) | ALDH1A1TSHRHPGDTHRBALOX15 | |
| Acrylic Acid Ethyl Ester SCHEMBL259713 | 0.90 | ALDH1A1 (0.40) | ALDH1A1TSHRHPGDTHRBALOX15 | |
| Acrylic Acid Ethyl Ester SCHEMBL5827836 | 0.90 | ALDH1A1 (0.44) | ALDH1A1TSHRHPGDTHRBHSD17B10 | |
| Acrylic Acid Ethyl Ester SCHEMBL28021684 | 0.90 | ALDH1A1 (0.44) | ALDH1A1TSHRHPGDTHRBHSD17B10 | |
| Acrylic Acid Ethyl Ester SCHEMBL12100195 | 0.88 | ALDH1A1 (0.41) | ALDH1A1TSHRHPGDTHRBALOX15 | |
| Trimethylammonium SCHEMBL6326203 | 0.88 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| Trimethylammonium SCHEMBL7355812 | 0.88 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB | |
| Trimethylammonium SCHEMBL7354581 | 0.88 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120294938-A1 | PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION | Dr. R. Pflefger Chemische Fabrik GmbH (DE) | 2012-11-22 | — | — | US | claimed |
| EP-1880718-B1 | Pharmaceutical preparation for oral administration with controlled drug release in the small intestine colon and process of prepartion thereof | PFLEGER R CHEM FAB (DE) | 2011-09-21 | — | — | EP | claimed |
| US-20090285891-A1 | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | DR. R. PFLEGER CHEMISCHE FABRIK GMBH (DE) | 2009-11-19 | — | — | US | claimed |
| US-7611730-B2 | Tramadol-based medicament | GRUNENTHAL GMBH (DE) | 2009-11-03 | — | — | US | claimed |
| EP-1372624-B1 | TRAMADOL-BASED MEDICAMENT | GRUENENTHAL GMBH (DE) | 2005-08-24 | — | — | EP | claimed |
| US-20040076669-A1 | Tramadol-based medicament | GRUNENTHAL GMBH (DE) | 2004-04-22 | — | — | US | claimed |
| US-4876092-A | SUSTAINED RELEASE; ACRYLIC POLYMERS, POLYOLS, DRUGS AND PLASTICIZER | TEIKOKU SEIYAKU KABUSHIKI KAISHA (JP) | 1989-10-24 | — | — | US | claimed |
| CN-117425471-A | Prolonged release compositions comprising tomoxetine | 图莱克斯制药公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-105813643-A | Methods of treating non-small cell lung cancer using pharmaceutical formulations containing thienotriazolodiazepine compounds | 翁科埃斯克斯有限公司 | 2016-07-27 | — | — | CN | disclosed |
| US-9132101-B2 | Administration form based on cross-linked hydrophilic polymers | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2015-09-15 | — | — | US | disclosed |
| EP-2832730-A1 | MIRABEGRON-CONTAINING PHARMACEUTICAL COMPOSITION | Astellas Pharma Inc. (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20150031734-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MIRABEGRON | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20120294938-A1 | PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION | Dr. R. Pflefger Chemische Fabrik GmbH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-7510729-B2 | Time-release agents; mechanical/storage stability; tablets | BASF AKTIENGESELLSCHAFT (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20080286342-A1 | Form of Administration Based on Crosslinked Hydrophilic Polymers | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20070086955-A1 | Form of administration for controlling primary headaches | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2007-04-19 | — | — | US | disclosed |
| US-20070071796-A1 | Administration form based on cross-linked hydrophilic polymers | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20050106252-A1 | Combination of polyvinyl acetate with water-insoluble, acid-insoluble, or alkali-insoluble polymers used for the production of film coatings with highly controlled release and high stability | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-19 | — | — | US | disclosed |
| US-20040076669-A1 | Tramadol-based medicament | GRUNENTHAL GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031734-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MIRABEGRON | GCGR, GPR119, GLP1R | ALDH1A1 1800/4885TSHR 499/4885HPGD 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.